Prurigo nodularis (PN) is a common and debilitating condition with no treatments approved by the US Food and Drug Administration. Herein, we describe cases of PN effectively treated with dupilumab (Dupixent; Regeneron-Sanofi).
Four patients with chronic, treatment-resistant PN presented with classic PN clinical findings without any clinical evidence of atopy. Three of the 4 patients had biopsies to confirm the PN nodules. Treatment with mirtazapine, 15 mg nightly, superpotent topical steroid ointments, and topical calcineurin inhibitor ointments had failed in all 4 cases. All patients reported no change with sun exposure. Two of the 4 patients had undergone narrowband UV-B therapy without improvement.
Mollanazar NK, Elgash M, Weaver L, Valdes-Rodriguez R, Hsu S. Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis. JAMA Dermatol. 2019;155(1):121–122. doi:10.1001/jamadermatol.2018.3906
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: